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Abstract  
Hypofunctioning of the N-methyl-D-aspartate (NMDA)-receptor (NMDA-R) has been 
prominently implicated in the pathophysiology of schizophrenia (ScZ). The current study tested 
the effects of ketamine, a dissociative anesthetic and NMDA-R antagonist, on resting-state 
activity recorded with magnetoencephalography (MEG) in healthy volunteers. In a single-blind 
cross-over design, each participant (n = 12) received, on two different sessions, a subanesthetic 
dose of S-ketamine (0.006 mg/Kg) and saline injection. MEG-data were analyzed at sensor- 
and source- level in the beta (13-30 Hz) and gamma (30-90 Hz) frequency ranges. In addition, 
connectivity analysis at source-level was performed using transfer entropy (TE). Ketamine 
increased gamma-power while beta-band activity was decreased. Specifically, elevated 30-90 
Hz activity was pronounced in subcortical (thalamus and hippocampus) and cortical (frontal 
and temporal cortex) regions, whilst reductions in beta-band power were localized to the 
precuneus, cerebellum, anterior cingulate, temporal and visual cortex. TE analysis 
demonstrated increased information transfer in a thalamo-cortical network after ketamine 
administration. The findings are consistent with the pronounced dysregulation of high-
frequency oscillations following the inhibition of NMDA-R in animal models of ScZ as well as 
with evidence from EEG-data in ScZ-patients and increased functional connectivity during 
early illness stages. Moreover, our data highlight the potential contribution of thalamo-cortical 
connectivity patterns towards ketamine-induced neuronal dysregulation, which may be relevant 
for the understanding of schizophrenia as a disorder of disinhibition of neural circuits. 
 
Keywords: Ketamine, Neural Oscillations, MEG, Schizophrenia, Thalamus, Gamma-Band 
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1) Introduction   
Schizophrenia (ScZ) is a debilitating psychiatric condition characterized by positive (e.g., 
hallucinations and delusions) and negative symptoms (e.g., flat affect), as well as cognitive 
deficits. Recent evidence suggests that a deficit in excitation/inhibition (E/I) balance parameters 
may constitute a pathophysiological mechanism that could underlie impairments in cognition 
and certain clinical symptoms (1). This is because during normal brain functioning, the 
generation of coherently organized large-scale networks is critically dependent upon the 
activity of gamma-aminobutyric acid (GABA) inhibitory interneurons expressing the calcium 
(Ca2+) binding protein parvalbumin (PV) (2) and glutamatergic activation of PV interneurons 
(3), leading to rhythmic fluctuations of neuronal excitability at low  and high-frequency ranges 
(4).  
Specifically, NMDA-receptors number and functionality have been critically implicated 
in the pathophysiology of ScZ (5, 6) and abnormalities in glutamatergic transmission are a 
candidate mechanism for disturbed high frequency oscillations in the disorder. In-vivo and in-
vitro electrophysiological studies using NMDA-R antagonists have revealed an increase of 
spontaneous power at both low (30-60 Hz) and high (60-130 Hz) gamma-band ranges as well 
as at ripple frequencies (130-200 Hz) (7). In contrast, oscillations at lower-frequencies, such as 
in the theta-band, are reduced (7). Only a small number of studies have reported no effects (8) 
or a decrease (9). Different gamma-band frequencies, however, are not always equally 
modulated by ketamine and regional differences have been reported in some studies (8).  
In the current study, we investigated the impact of ketamine on resting-state activity in 
MEG-recordings in healthy volunteers to establish links between pre-clinical research and 
findings from EEG/MEG-recordings in ScZ-patients. Recent evidence from spontaneous EEG 
recordings in ScZ-patients has reported increased spontaneous high-frequency activity in ScZ 
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(10, 11) although this has not been confirmed in all studies (10). In addition, several studies 
with functional magnetic resonance imaging (fMRI) indicated increased connectivity in large-
scale networks following ketamine administration (12) which parallels findings in participants 
at-risk for psychosis and patients with first-episode ScZ (13).  
Together with findings of elevated glutamate levels in early-stage ScZ (14), these findings 
raise the possibility that NMDA-hypofunctioning may underlie certain neuronal signatures of 
the disorder, highlighting the need to investigate the effects of Ketamine on gamma-band 
oscillations in healthy volunteers. However, in humans, only preliminary evidence exists on 
increased gamma-band power at rest following ketamine-administration at subanesthetic 
dosages (15).  
 
2) Methods and Materials 
2.1) Participants 
Twelve participants (two females) with a mean age of 29.6 years (range: 27-39) were recruited 
and the structured Clinical Interview for DSM-IV (SCID-II) (16) was administered. If criteria 
were met for a past or present Axis I or II diagnosis, the participant was excluded from the 
study. Similarly, family history of a psychotic disorder led to exclusion from the study. The 
medical screening consisted of a physical examination along with regular ECG, vital signs, 
blood tests, drug screening and psychological testing (see Supplementary Methods for a list of 
the tests adopted). The study was carried out according to the Declaration of Helsinki and 
approved by the ethical committees of the Goethe University Frankfurt. After complete 
description of the study to the participants, written informed consent was obtained.  
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2.4) Experimental procedure 
At the beginning of the experimental session, a bolus of 10 mg S-ketamine (drug condition) or 
10 ml of NaCl 0.9% (placebo condition) was injected. This was followed by continuous 
intravenous infusion at 0.006 mg S-ketamine per Kg body weight per minute or NaCl 0.9%, 
respectively. We recorded eight minutes (four minutes with eyes open and four minutes with 
eyes closed) of resting-state activity during the continuous drug (ketamine or placebo) infusion. 
Only the eyes closed condition will be reported. Resting state activity was recorded circa 45 
minutes after bolus injection, time in which participants performed a visual task (data not 
reported here). Following the MEG-recording, participants were examined using the Positive 
and Negative Syndrome Scale (PANSS) (17) with the addition of the ‘disorganization’ factor 
(18).  
 
2.5) Anatomical MRI data acquisition 
Prior to the MEG-measurement, a high-resolution anatomical MRI scan was acquired for each 
participant using a 3D magnetization-prepared rapid-acquisition gradient echo sequence (160 
slices; voxel size: 1x1x1 mm; FOV: 256 mm; TR: 2300 ms; TE: 3.93 ms). Scanning was 
performed using a 3-Tesla Siemens Trio scanner. 
 
2.6) MEG-data acquisition 
MEG data were acquired using a 275-sensors whole-head system (Omega 2005, VSM 
MedTech Ltd, BC, Canada) at a sampling rate of 600 Hz in a synthetic third order axial 
gradiometer configuration. Data were band-passed filtered offline between 1-150 Hz, and 
participants’ head movements were monitored before and after each recording using coils 
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placed on the nasion and 1 cm anterior of the tragus of the left and right ear. Head movements 
were monitored before and after the recording. Recordings with movements larger than 5 mm 
were excluded from the analysis. 
 
2.7) MEG data processing and analysis  
Preprocessing and analysis of the MEG data was performed with the open source Matlab 
toolbox “FieldTrip” (19). The continuous recording was divided in segments of 2 seconds, each 
constituting a trial. Trials containing eye blinks or artifacts due to muscle activity or sensors 
(SQUIDs) jumps were discarded using automatic artifact rejection routines. Data were 
processed and statistically analyzed both at the sensor- and at the source-level. In addition, to 
investigate the effects of ketamine on the interactions between “drug-reactive” sources, we 
quantified changes in information transfer by measuring transfer entropy (TE) (20), as 
implemented in the TRENTOOL toolbox (21, 22).  
 
2.7.1) Sensor- and source- level analysis 
Sensor-level beta (13-30 Hz) and gamma (30-90 Hz) frequency activity was estimated using 
Morlet-wavelet convolution (5 cycles per wavelet). A non-parametric dependent samples t-test 
based on a permutation approach (1500 permutations) (23) was used to test differences between 
the placebo and ketamine conditions on all MEG sensors. To minimize the influence of 
differences in the distance between MEG-sensors and head position on amplitude fluctuations, 
data was normalized both for high and low frequency analysis by dividing the amplitude of 
each frequency by the sum of the amplitudes of all frequencies.  
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Power-spectra were source-localized using a Dynamical Imaging of Coherent Sources 
(DICS) frequency beamformer (24). Single-subject source power estimates were normalized to 
the template brain of the Montreal Neurological Institute (MNI) using SPM8 
(http://www.fil.ion.ucl.ac.uk/spm). Source data were statistically analyzed using cluster-based 
permutations (1500 permutations). 
 
2.7.2) Transfer Entropy (TE) 
Source-level functional connectivity between regions showing spectral changes after ketamine 
administration (see Results section below) was estimated using TE (25, 26). TE estimates the 
amount of information communicated from a source to a target process. This is achieved by 
quantifying how much information in the future of  the target process is only predictable when 
knowing the past states of the source process. In this sense, TE can be seen as a more general, 
information theoretic version of Wiener-Granger causality (see Supplementary information for 
details on TE analysis). In the first step of our analysis, we extracted the time-course (i.e., virtual 
channels) of all sources showing ketamine-reactivity in the beta and gamma bands. We then 
assessed the global, drug-driven, change in TE between all sources through averaging TE values 
across all links per participant and conditions. To localize these changes across the links post-
hoc, a one-sided permutation test for each link was performed and the alpha level was corrected 
for multiple comparisons using bonferroni correction. Given the number of sources (n = 16) 
and the number of potential interactions for each source (n = 15), p was set to 0.05 / 240 (2.08 
* 10-4). In addition, we investigated TE-changes separately for interactions between sources in 
the beta- and gamma-frequency ranges as well as between source that were active in two 
different spectral bands. 
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3) Results 
3.1) PANSS-Data 
Ketamine lead to a statistically significant increase in all of the six PANSS subscales (see Figure 
1 and Table S1).  
 
3.2) Sensors- and source- level MEG results 
After artifact rejection, 77 trials (SD = 21) remained in the placebo and 84 trials (SD = 12) in 
the ketamine condition. Ketamine administration caused an increase in gamma-band (30-90 
Hz) power over frontal, parietal and temporal MEG sensors (see Figure 2). Similar to the 
sensor-level results, source-analysis demonstrated an increase in the gamma-band frequency 
range following ketamine administration in a number of cortical and subcortical regions. 30-90 
Hz power was most prominently increased in the right hippocampus and right/left thalami, 
followed by cortical structures, such as the left fusiform gyrus, right medio frontal cortex, left 
frontal pole, left superior frontal gyrus, left superior temporal gyrus and left middle temporal 
gyrus (see Figure 3 and Table S2).  
In contrast to gamma-band power, beta-band (13-30 Hz) activity was reduced after 
ketamine administration in particular over central MEG sensors. At the source-level, beta-band 
decreases were localized to the cerebellum, left/right precunei, right middle temporal gyrus, left 
anterior cingulate cortex, right inferior temporal gyrus and visual cortex (see Figure 3 and Table 
S3).  
 
3.3) Correlation between MEG-source activity and PANNS 
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Source-power in two anatomical regions showing the strongest ketamine effect in the gamma-
band range (right hippocampus and right thalamus) were correlated to the PANSS subscales 
using a non-parametrical Spearman correlation. Results showed a negative correlation between 
right hippocampus power after ketamine injection and PANSS Positive scale (rs(12) = -0.70, p 
= .011).  
 
3.4) Transfer entropy results 
Ketamine administration caused an increase in the average TE-values (see Figure 5A for 
uncorrected effects). Connections that survived multiple comparisons correction were localized 
to links from left middle temporal gyrus (MTG-L) to right inferior temporal gyrus (ITG-R); 
ITG-R to the left Thalamus (Th-L, ); Th-L to right visual cortex (Visual Cortex-R); Visual 
Cortex-R to right precuneus (Prec-R); Prec-R to Th-L (Figure 5B). Connections with significant 
increases in information transfer were found for source pairs comprising three of four possible 
types: between sources with ketamine-induced changes in the beta-band, between sources with 
changes in the gamma band, and from sources with changes in the gamma band to sources with 
changes in the beta band. Changes in TE values for the remaining type, from sources with 
changes in the beta band to sources with changes in the gamma band were found at slightly less 
conservative thresholds of p < 0.0005 (Figure 5 D). For the purpose of comparison we also 
present the other connection types at this threshold (Figure 5, C, E).   
  
4) Discussion 
There is increasing evidence suggesting that core features of ScZ may be the consequence of 
hypofunctioning of NMDA-receptors (5). In the current study, we investigated the effects of 
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ketamine, a noncompetitive antagonist of the NMDA-R, on resting-state MEG-activity in 
healthy volunteers, to establish whether changes in amplitude fluctuations and connectivity 
patterns following ketamine administration allow links to the pathophysiology of ScZ. 
Currently, only preliminary evidence exists on the effects of ketamine in humans on 
spontaneous beta/gamma-band activity (15). Our findings of pronounced increases in gamma-
band power and increased functional connectivity are in agreement with extensive pre-clinical 
data on the effects of ketamine on neural oscillations (27-32). Moreover, there are similarities 
with evidence from EEG and fMRI-recordings in ScZ (13, 33), which together have potentially 
important implications for the understanding of ScZ as a disorder involving fundamentally a 
disinhibition of cortico-subcortical circuits.  
 
Ketamine Effects on High-frequency activity: Potential neurophysiological mechanisms 
The spectra during resting-state activity corresponded to the usual 1/f distribution both in the 
placebo and in the ketamine condition. The contrast between ketamine-induced spectral activity 
and the placebo condition, however, suggests an upregulation of high-frequency activity with a 
peak ~ 60 Hz (Figure 4b). The frequency as well as the magnitude of this effect are comparable 
to visually-induced activity that has been described in recent MEG-studies (34), suggesting that 
NMDA-R hypofunctioning could be associated with an oscillatory process in cortical and 
subcortical regions. In contrast to 30-90 Hz power, beta-band activity was strongly reduced, 
which is in agreement with recent data (35).  
Source-reconstruction of resting-state MEG-activity allowed us to determine the neural 
generators in different frequency ranges. In the 30-90 Hz frequency band, ketamine caused an 
upregulation in subcortical and cortical areas. The largest increases of gamma-band activity 
were observed in the right hippocampus and right/left thalami, followed by parietal, temporal 
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and frontal structures (Figure 3). This is in agreement with previous in-vivo studies in rodents 
(9, 27, 36-38), which consistently demonstrated a ketamine-induced increase in spontaneous 
gamma-band activity in cortical and subcortical areas. Decreases in beta-band were localized 
to brain regions that were overall distinct from gamma-band generators. Maximal reductions in 
13-30 Hz were localized, for example, to the cerebellum, temporal and visual cortex.  
Potential mechanisms for the ketamine-driven upregulation of gamma-band activity are 
increased excitability of pyramidal cells due to reduced activation of GABAergic interneurons 
and a shift in the relative contribution of AMPA and NMDA-R mediated excitatory post 
synaptic potentials (EPSPs) to the drive of interneurons (39). Previous studies have shown that 
NMDA-R hypofunction leads to an increase in firing rate of pyramidal neurons (40). In 
addition, AMPA receptor mediated excitation becomes relatively more preponderant when 
NMDA-Rs are deficient as AMPA-R mediated EPSPs have much faster kinetics than NMDA-
R mediated EPSPs and are more numerous than NMDA-Rs on PV+-interneurons (41). 
Accordingly, reducing the NMDA-R mediated excitatory input on GABAergic interneurons 
increases the ratio of fast over slow EPSPs (39) and this, together with increased activity of 
pyramidal cells, provides favorable conditions for fast oscillations with important implications 
for information processing and network-interactions.  
Gamma-band oscillations are particularly prominent in superficial layers (layers 2/3) 
(42), the main origin of feedforward projections, and are dependent upon fast, transient 
excitation of fast-spiking interneurons (43). In contrast, beta oscillations are largely found in 
infragranular layers and can be independent of excitatory or inhibitory synaptic transmission 
(44). Current theories suggest that beta-band oscillations are therefore involved in the mediation 
of feedback to lower sensory areas and important for predictive coding processes (45). 
Accordingly, one effect of the NMDA-R hypofunctioning is a possible shift towards feed-
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forward mediated information transmission and/or increase in background activity which could 
interfere with incoming sensory information. As a result, a decrease in signal-to-noise in neural 
circuits occurs (46, 47) which could impact upon the ability to differentiate between relevant 
and irrelevant information, a symptom commonly observed in the early stages of ScZ (48). 
This hypothesis is supported by our result of increase functional connectivity (TE) 
between sources, which included the thalamus, hippocampus, parietal and temporal cortices. 
Increased TE-values have to be interpreted as information in one source closely following 
information available in another source (26). Thus, at an information theoretical level, our data 
suggests that MEG-derived generators follow more readily the input they receive, which could 
further amplify the shift towards a higher-frequency regime and thus contribute to a breakdown 
of filtering capabilities with respect to a source's input.  
 
NMDA-R, Gamma-Band Activity, Network Organization and ScZ 
An important question concerns the similarities between the changes in rhythmic activity and 
connectivity patterns resulting from NMDA-R hypofunction in the current study and the 
evidence on abnormal large-scale network-activity in ScZ-patients. As pointed above, ketamine 
and associated NMDA-R hypofunction lead to an upregulation of high-frequency activity and 
increased interactions between nodes of the network.  
Currently, the large majority of studies in patients with ScZ have reported decreases of 
task related gamma band power (49) and connectivity (50, 51), which is inconsistent with this 
finding. However, a recent study (33) showed that background gamma activity is increased 
during auditory steady-state stimulation in SZ which was interpreted as a disruption in E/I-
balance parameters, possibly resulting from NMDA-R hypofunctioning. This is furthermore 
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supported by preliminary evidence for increased gamma-band in medication-naïve first-episode 
ScZ-patients at-rest (11, 52) which has not, however, been confirmed in other studies (10, 49, 
53).  
Additional evidence supporting the relationship between the role of glutamatergic 
abnormalities and neurophysiological dysfunctions in ScZ comes from several studies that have 
examined functional connectivity in early-stage ScZ with resting-state fMRI. Consistent with 
our finding of increased connectivity in thalamo-cortical circuits, individuals at high risk for 
ScZ and patients with early-course ScZ were characterized by increased connectivity which 
was not present in chronic ScZ-patients (13).   
The possibility of NMDA-R mediated disinhibition in ScZ at illness-onset is supported 
by our recent data in unmedicated first-episode-ScZ patients which suggests an excessive 
spreading of neural activity as indexed by event-related fields during sensory processing in 
MEG-data (54), as well as by findings suggesting elevated glutamate levels during early illness 
stages which decrease progressively with illness duration (14). Accordingly, these findings 
highlight the possibility of a stage-specific elevation of network-activity and organization, 
which is compatible with a large-scale disinhibition of neural circuits in ScZ.   
Our results of MEG-informed source-localization furthermore are consistent with recent 
data that have highlighted the importance of thalamo-cortical interactions and hippocampal 
circuits in the pathophysiology of ScZ. Several resting-state fMRI studies reported increased 
functional connectivity between thalamus and cortical regions (55-57), albeit some report 
mixed findings (57). In addition, the increase in gamma-band activity in hippocampal sources, 
a brain region with a large number of NMDA-receptor sites (58), is consistent with findings 
highlighting the possible contribution of elevated metabolism as a result of NMDA-R 
hypofunctioning in the early stages of ScZ (59). 
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Issues for further Research and Limitations  
It should be noted that the interpretation of the physiological effects of ketamine is complicated 
by the fact that, in addition to blocking NMDA-Rs, ketamine also increases the systemic levels 
of dopamine, acetylcholine, and norepinephrine (60). However, more recent evidence suggests 
that the increase in gamma-band activity is mainly due to a specific blockade of NMDA 
receptors containing the NR2A subunit (61).  
In addition, several brain regions with significant modulation at beta/gamma-band 
frequencies were localized to subcortical areas (thalamus and hippocampus). Albeit MEG 
subcortical source localization remains challenging due to the rapid decay of the neuromagnetic 
field in function of the head-sensors distance, recent studies have however reported robust 
signals obtained from thalamic and hippocampal sources (62-64), suggesting the potential 
suitability of MEG to detect rhythmic activity from deeper brain regions. 
The important role of the thalamus in the dysregulation of high-frequency oscillations in 
our MEG-data is supported by previous findings showing that the thalamus is centrally involved 
in the regulation of synchronous cortical activity and in the gating of sensory information (65). 
Specifically, there is a large body of evidence showing that gamma-band oscillations are robust 
signature of thalamic activity as indicated by pacemaker function of cells in the thalamic 
reticular nucleus (RT) in the generation of 40 Hz-oscillations (66), and pronounced 30-90 Hz 
oscillations in the lateral geniculate nucleus (LGN) (67). 
Moreover, data from animal model indicate that ketamine reduces extracellular GABA 
levels by acting on NMDA-R PV interneurons (68). In particular, GABA release reduction from 
the RT to other thalamic nuclei, due to inactivation of NMDA-R on RT-neurons, would lead to 
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increase firing rate of thalamic relay neurons and pathological activation of thalamo-cortical 
circuits, which could trigger a widespread shift in excitability levels (69).  
This evidence is consistent with current findings of thalamic-driven dysregulation of 
connectivity patterns following acute ketamine administration (70). Together, these findings 
highlight an important convergence between pre-clinical findings and MEG-reconstructed 
resting-state networks that identify the thalamus as a core region of ketamine-induced network 
changes. Moreover, NMDA-R blockade by ketamine increases global-based connectivity (12) 
and increased functional inputs to regions such as the thalamus, frontal lobe and occipital 
cortex, in human fMRI resting-state recordings. 
 
Summary 
The findings of the current study support previous data from invasive electrophysiological 
investigations, which have demonstrated a profound effect of NMDA-hypofunction on 
coordinated high-frequency activity (7, 29). Because some evidence suggests that 
spontaneous gamma-band power may be increased in ScZ-patients, especially at illness-onset 
(71), and because gamma-band activity is constitutive for cognition and normal brain 
functions (1), it is important to further identify the mechanisms through which ketamine leads 
to the upregulation of gamma-band activity. This will require an integration of both targeted 
pharmacological studies in in-vitro and in-vivo preparations as well as further investigations 
of the connectivity and dynamics of large-scale neuronal networks. Further research into the 
mechanisms underlying the effects of NMDA-R on high-frequency activity promises insights 
into the role of beta/gamma-band oscillations for normal brain functions, the pathophysiology 
of ScZ, but also of affective disorders, such as depression, since ketamine has recently been 
demonstrated to act rapidly as an anti-depressant (72). 
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Figure legends 
 
 
Figure 1. Average scores on the six different PANSS subscales for the placebo (black) and 
ketamine (gray) conditions. Error bars indicate the s.e.m. (* = p < .05).  
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Figure 2. Sensor-level analysis. (A) Topoplots representing the average power spectra (fT) of 
gamma (top) and beta (bottom) frequency ranges in the placebo (left) and ketamine (right) 
conditions. (B) Results of the non-parametric cluster-based statistic highlighting sensors 
showing a statistically significant effect for gamma (top) and beta (bottom) frequencies. Red 
colors indicate a statistically significant difference in favor of the ketamine condition, whereas 
blue colors indicate a difference in favor of the placebo condition (* = p < .001).  
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Figure 3. Source-level analysis. Cluster-based non-parametric statistic highlights statistically 
significant differences between the placebo and ketamine condition across the gamma (left) and 
beta (right) frequency bands (red: ketamine > placebo; blue: placebo > ketamine). Gamma-
band (30-90 Hz): 1. R-hippocampus [10 -10 -20], 2. R-thalamus [10 -10 10], 3. L-thalamus [-
10 -20 10], 4. L-fusiform gyrus [-40 -10 -30], 5. R-medial frontal cortex [0 40 -20], 6. L-frontal 
pole [-20 40 -10], 7. L-superior frontal gyrus [-20 40 40], 8. L-superior temporal gyrus [-70 -
20 0], 9. L-middle temporal gyrus [-60 0 -30]. Beta-band (13-30 Hz): 1. cerebellum [0 -40 -20], 
2. L-precuneus [-20 -50 20], 3. R-precuneus [30 -50 10], 4. R-middle temporal gyrus [60 -30 -
10], 5. L-anterior cingulate [0 20 -10], 6. R-inferior temporal gyrus [50 -60 -20], 7. R-visual 
cortex [30 -90 -10]. 
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Figure 4 . Power spetra analysis. (A) Placebo and ketamine power-spectra as averaged across 
all subjects and calculated considering all MEG sensors (shades indicated the s.e.m.). (B) 
Relative change (i.e., ((Ketamine power – Placebo power) / Placebo power) * 100) of the 
ketamine power with respect to the placebo power in the gamma-band range.  
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Figure 5. Transfer entropy (TE) analysis. TE differences between ketamine and placebo 
conditions. Green diamonds indicate MEG sources reactive to ketamine in the gamma band, 
blue circles indicate sources reactive in the beta band (see Figure 3). Arrow colors indicate 
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strength of the difference. (A) Uncorrected differences in TE.  (B) Statistically significant 
differences (Bonferroni corrected: p < 2.08*10-4). For illustration purposes we also provide the 
TE differences at a significance threshold of p < 0.0005 uncorrected, for the transfer entropy 
between (C) sources reactive in the beta frequency band, (D) in the gamma frequency band, 
and (E) between beta- and gamma-sources. Legend: FrontalPole-L = left frontal pole, MFC = 
medial frontal cortex, SFG-L = left superior frontal gyrus, ACC = anterior cingulate cortex, 
MTG-L = left middle temporal gyrus, FuG-L = left fusiform gyrus, Th-L= left thalamus, Cb = 
cerebellum, Prec-L = left precuneus, HI-R = right hippocampus, Th-R = right thalamus, MTG-
R = right medial temporal gyrus,Prec-R = right precuneus,  ITG-R = right inferior temporal 
gyrus, VisualCortex-R = right visual cortex. 
 
